Fig. 6
IL-17A and IL-23 promote increased disease incidence in Ifng–/–Bigenic mice. a Prevalence of a wasting phenotype among Il17a–/–Ifng–/–Bigenic (n = 39), Ifng–/–Bigenic (n = 38) and Bigenic (n = 159) mice during the juvenile period. b Weight change rate during the juvenile period following initial manifestation of the wasting phenotype for Il17a–/–Ifng–/–Bigenic (n = 29), Ifng–/–Bigenic (n = 46) and Bigenic (n = 41) mice. c, d Ileal crypt depths (c) and colitis scores (d) for juvenile Il17a–/–Ifng–/–BigenicNS (n = 6), Il17a–/–Ifng–/–BigenicS (n = 18), Ifng–/–Bigenic (n = 17) and Bigenic (n = 19) cohorts. Symptomatic cohorts include mice euthanized before juvenile age (Il17a–/–Ifng–/–Bigenic n = 10; Ifng–/–Bigenic n = 15). e Prevalence of a wasting phenotype among IL-23R blockade treated Ifng–/–Bigenic (21A4; n = 15), isotype control treated Ifng–/–Bigenic (ISO; n = 9), Ifng–/–Bigenic (n = 50) and Bigenic (n = 157) mice during the juvenile period. f Weight change rate during the juvenile period following initial manifestation of the wasting phenotype for 21A4 (n = 4), ISO (n = 9), Ifng–/–Bigenic (n = 50) and Bigenic (n = 157) mice. g, h Ileal crypt depths (g) and colitis scores (h) for juvenile 21A4 (n = 10), ISO (n = 9), Ifng–/–Bigenic (n = 16) and Bigenic (n = 19) mice. Symptomatic mouse cohorts include mice euthanized before juvenile endpoint (ISO n = 6; Ifng–/–Bigenic n = 15). i 3A9+Treg and 3A9–Treg cell numbers from mLN. Juvenile 21A4 (n = 10), ISO (n = 9), Ifng–/–Bigenic (n = 25) and Bigenic (n = 22) mice shown. Most Ifng–/–Bigenic mice required euthanasia before juvenile endpoint (n = 21)
